A comparative analysis of the consumption of medicines from the group of calcium channel blockers in Ukraine and some European countries
DOI:
https://doi.org/10.24959/sphhcj.25.363Keywords:
arterial hypertension; calcium channel blockers; European countries; consumption; pharmaceutical market; ATC/DDD methodologyAbstract
Calcium channel blockers have long remained an important class of antihypertensive agents due to their clinical benefits in the treatment of patients at high risk of cardiovascular, cerebrovascular, and renal complications.
Aim. To analyze the dynamics of drug consumption in the group of calcium channel blockers in Ukraine (for 2021-2023) and compare the consumption indicators with data from some European countries, in particular Estonia, Croatia, and Norway.
Materials and methods. The study was conducted using data from the State Register of Medicines of Ukraine and the analytical system for pharmaceutical market research “Proxima Research” of the company “Morion”. The consumption analysis of the drugs studied was performed using the ATC/DDD methodology recommended by the WHO. The indicator of DDDs per 1,000 inhabitants per day (DID) was used as the unit of measurement. Data on the calcium antagonist consumption in other European countries were obtained from the relevant national registries.
Results and discussion. It was found that the consumption of calcium antagonists in the domestic pharmaceutical market during 2021-2023 fluctuated slightly from 23,624 DID to 21,437 DID, i.e. it decreased by 9.26 %. The highest consumption volumes were for amlodipine (from 17,845 DID in 2021 to 15,245 DID in 2023), lercanidipine (from 2.43 DID in 2021 to 3.21 DID in 2023) and nifedipine (from 1,464 DID in 2021 to 1,196 DID in 2023). The highest consumption among combined drugs based on calcium channel blockers was observed for drugs combining amlodipine with indapamide. During the period analyzed, their consumption increased by 15 %. A comparison of the consumption of medicines from the group of calcium channel blockers in Ukraine, Croatia, Estonia, and Norway shows both numerous similarities and individual national differences. In all the countries considered, the leading positions in terms of consumption are occupied by amlodipine and lercanidipine. In Norway and Ukraine, the consumption of nifedipine remains stable, ranking third in the structure of the group analyzed. Estonia is characterized by a significant intake of nitrendipine, the share of which was 8.64 % in 2022 and 8.15 % in 2023. At the same time, a feature of the pharmaceutical markets of Croatia and Estonia is the relatively high level of lacidipine consumption.
Conclusions. The analysis of the consumption of calcium channel blockers in 2022–2023 revealed both pan-European trends and country-specific features of pharmacotherapeutic practice. In all the countries studied, the highest consumption volumes are for amlodipine drugs. Lercanidipine consistently occupies the second position, demonstrating a gradual increase in consumption. At the same time, individual approaches to the prescription of calcium channel blockers are observed in each country; they are formed under the influence of national experience, pricing policy and the level of availability of individual drugs in the domestic market.
References
Huz, V., & Revyatskyy, I. (2024). Systematic analysis of the theoretical arsenal of antihypertensive drugs in Ukraine. Annals of Mechnikov Institute, (1), 59–70. https://doi.org/10.5281/zenodo.10838296
STEPS: prevalence of noncommunicable disease risk factors in Ukraine 2019. (2020). Copenhagen: WHO Regional Office for Europe. https://ukraine.un.org/en/101307-steps-prevalence-noncommunicable-disease-risk-factors-ukraine-2019
Lu, W. L., Yuan, J. H., Liu, Z. Y., Su, Z. H., Shen, Y. C., Li, S. J., & Zhang, H. (2024). Worldwide trends in mortality for hypertensive heart disease from 1990 to 2019 with projection to 2034: data from the Global Burden of Disease 2019 study. European journal of preventive cardiology, 31(1), 23–37. https://doi.org/10.1093/eurjpc/zwad262
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., Azizi, M., Benetos, A., Borghi, C., Hitij, J. B., Cifkova, R., Coca, A., Cornelissen, V., Cruickshank, J. K., Cunha, P. G., . . . Kjeldsen, S. E. (2023). 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of hypertension, 41(12), 1874–2071. https://doi.org/10.1097/HJH.0000000000003480
Ferri, N., Corsini, A., & Pontremoli, R. (2022). Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril. European review for medical and pharmacological sciences, 26(20), 7482–7492. https://doi.org/10.26355/eurrev_202210_30018
Kocherzhat, O. I., Haman, I. O., Vasilechko, M. M., Neiko, V. Ye., Dzvonkivska, V. V., & Vatseba, B. R. (2025). Efektyvnistʹ i bezpechnistʹ kombіnovanoi antyhipertenzivnoi terapii z vkliuchenniaм lercanidypinu ta kandesartanu u khvorykh iz metabolichnym syndrome. Art of Medicine, 33(1), 58–62. https://doi.org/10.21802/artm.2025.1.33.58
Tocci, G., Desideri, G., Roca, E., Calcullo, C., Crippa, M., De Luca, N., Gaudio, G. V., Lonati, L. M., Orselli, L., Scuteri, A., Vulpis, V., Acone, B., & Zaninelli, A. (2017). How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension. High Blood Pressure & Cardiovascular Prevention, 25(1), 25–34. https://doi.org/10.1007/s40292-017-0242-z
Yakovlieva, L. V., Mishchenko, O. Ya., & Adonkina, V. Yu. (2017). Pharmacoepidemiological studies of the volume of antihypertensive drug consumption in Ukraine: monograph. National University of Pharmacy.
Mishchenko, M., Bilyk, A., Tsvyk, O., & Bondarenko, O. (2016). Analysis of Affordability and Consumption of Antihypertensive Fixed Combinations of Drugs in Ukraine. Value in Health, 19(7), A661.
Demchuk, M. B., Malanchuk, N. V., Pokotylo, O. O., Pavlyshyn, S. H., & Stechyshyn, I. P. (2025). Porivnial’ni doslidzhennia spozhyvannia beta-adrenoblokatoriv v Ukraini ta deiakykh krainakh Yevropy. Pharmaceutichnyi chasopys, (1), 65–73. https://doi.org/10.11603/2312-0967.2025.1.15272
Derzhavnyi reiestr likarsʹkykh zasobiv Ukrainy. Derzhavnyi ekspertnyi tsentr Ministerstva okhorony zdorovia Ukrainy. http://www.drlz.com.ua
Kompendium. https://compendium.com.ua/uk/
ATC/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology. https://www.whocc.no/atc_ddd_index/
Ukraine population growth rate 1950–2025. Macrotrends. https://www.macrotrends.net/global-metrics/countries/UKR/ukraine/population-growth-rate
Estonian Statistics on Medicines 2022-2023. https://ravimiamet.ee/sites/default/files/documents/2024-11/Ravimiamet_aastaraamat_2024.pdf
Drug Consumption in Norway 2019-2023. Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database. https://www.fhi.no/contentassets/b0802ad9303347b682cf6a8fa701ec91/legemiddelforbruket-i-norge-2019-2023-rapport-2024.pdf
Report on medicine consumption in the Republic of Croatia. Agency for Medicinal Products and Medical Devices. https://www.halmed.hr/
Nakaz MOZ Ukrainy “Pro zatverdzhennia Perelikiv likarskykh zasobiv i medychnykh vyrobiv, yaki pidliahaiut reimbursatsii za prohramoiu derzhavnykh harantii medychnoho obsluhovuvannia naselennia, stanom na 10 serpnia 2023 roku” No. 1495 (2023, August 21). https://zakon.rada.gov.ua/rada/show/v1495282-23#TextMinistry of Health of Ukraine.
Kasekamp, K., Habicht, T., Võrk, A., Köhler, K., Reinap, M., Kahur, K., Laarmann, H., & Litvinova, Y. (2025). Estonia: Health system summary, 2024 (updated). European Observatory on Health Systems and Policies, WHO Regional Office for Europe. https://iris.who.int/bitstream/handle/10665/381431/9789289059978-eng.pdf?sequence=1
Saunes, I. S., Durvy, B., & Litvinova, Y. (2024). Norway: Health system summary, 2024. European Observatory on Health Systems and Policies, WHO Regional Office for Europe. https://ticaret.gov.tr/data/5b8a43355c7495406a227616/Norway-%20Health%20system%20summary%202024.pdf
Džakula, A., Vočanec, D., Banadinović, M., Vajagić, M., Lončarek, K., Lukačević Lovrenčić, I., Radin, D., & Rechel, B. (2024). Croatia: Health system summary, 2024. European Observatory on Health Systems and Policies, WHO Regional Office for Europe. https://iris.who.int/bitstream/handle/10665/379910/9789289059961-eng.pdf?sequence=1
Kireyev, I. V., Zhabotynska, N. V., Tsemenko, K. V., Bakumenko, M. G., & Olishchuk, I. P. (2023). The role of a clinical pharmacist in implementing modern guidelines for the pharmacotherapy of arterial hypertension. Social Pharmacy in Health Care, 9(4), 31–38. https://doi.org/10.24959/sphhcj.23.303
Jones, K. E., Hayden, S. L., Meyer, H. R., Sandoz, J. L., Arata, W. H., Dufrene, K., Ballaera, C., Lopez Torres, Y., Griffin, P., Kaye, A. M., Shekoohi, S., & Kaye, A. D. (2024). The evolving role of calcium channel blockers in hypertension management: Pharmacological and clinical considerations. Current Issues in Molecular Biology, 46(7), 6315–6327. https://doi.org/10.3390/cimb46070377
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
